According to the Presidency´ official Twitter account, the meeting also assessed the encouraging outcomes of the clinical studies of Jusvinza drug for treating rheumatoid arthritis, a disease that is currently affecting more than 136,000 Cubans.
The new drug -produced by the Cuban Center for Genetic Engineering and Biotechnology (CIGB, in Spanish)- has also shown high effectiveness in Covid-19 patients.
Jusvinza is the first therapeutic product in Cuba based on synthetic peptide. It improves ventilatory parameters and inflammation markers, which leads to the recovery of Covid-19 people.
In a similar meeting last October, DSc. María del Carmen Domínguez presented the Jusvinza (CIGB-258) results, which have allowed high levels of recovery of seriously-ill patients.
The same positive effects were achieved with the application to pregnant women (to reduce extremely serious maternal morbidity and maternal mortality), she reported.
Jusvinza could be used to treat rheumatoid arthritis, juvenile idiopathic arthritis, which affects children, and sepsis, specifically community-acquired pneumonia.